Source comparison
Melanotan-2 Skin Pigmentation Complete Guide 2026: Research Applications vs Cosmetic Use
Dermatology Research (photoprotection studies) 0.25–0.5mg daily for 10–14 days, then 0.25mg 3× weekly maintenance 7–10 days visible darkening 4–6 weeks post-cessation Regular skin assessments, adverse event logging Controlled setting with institutional oversig
This comparison does not assign a generated winner or score.
- Dermatology Research (photoprotection studies)
- 0.25–0.5mg daily for 10–14 days, then 0.25mg 3× weekly maintenance
- 7–10 days visible darkening
- 4–6 weeks post-cessation
- Regular skin assessments, adverse event logging
- Controlled setting with institutional oversight and defined endpoints
- Metabolic Research (MC4R cross-reactivity studies)
- Variable dosing to assess receptor selectivity, typically 0.1–1.0mg range
- Secondary observation, not primary endpoint
- N/A
- Cardiovascular monitoring due to MC3R/MC4R effects
- Primary focus on appetite/energy expenditure, not pigmentation
- Unregulated Cosmetic Use
- Inconsistent dosing, often exceeding research ranges, no medical supervision
- Highly variable depending on source purity and individual response
- Unpredictable
- No systematic monitoring; adverse events unreported
- Lacks institutional review, standardised dosing, or quality-verified peptide source
- MT-2's classification as a research peptide means it is not FDA-approved for cosmetic tanning or any therapeutic indication. Clinical trials investigating its use for photoprotection in patients with erythropoietic protoporphyria (a rare photosensitivity disorder) showed efficacy, but the compound has not advanced to regulatory approval. This distinction matters: research-grade peptides are synthesised for investigational use under institutional protocols, not for consumer self-administration.
- The primary safety concern in uncontrolled use is the lack of purity verification and dosing precision. Compounded or gray-market MT-2 may contain impurities from incomplete synthesis, bacterial endotoxins from contaminated reconstitution, or inconsistent peptide concentration that makes accurate dosing impossible. Without third-party analytical testing (HPLC, mass spectrometry), there's no way to confirm what's in the vial.